CF Foundation’s Drug Discovery Investment Leads Galapagos to Pursue CF Drug Development
| 1 min read

A Belgium biotech company called Galapagos announced it will pursue cystic fibrosis drug development, following a successful collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation.

CFFT invested $3.2 million in a drug discovery program with Galapagos to discover drug targets that could potentially lead to successful therapies. The program resulted in the identification of 19 targets, setting the stage for drug development.

“We are pleased that Galapagos has joined the effort to find effective therapies to fight cystic fibrosis,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. “This is another success for the Foundation's Therapeutics Development Program and furthers our mission of developing new drugs for the CF community.”

Read the Galapagos release.

Share this article
Topics
Research
Recent news
CF Foundation Reflects on Progress Toward Equity, Racial Justice, Diversity, and Inclusion
News | 4 min read
CF Foundation Invests Up to $3.5M in Gensaic for Novel Gene Delivery Method
News | 2 min read
CF Foundation Urges Vertex Pharmaceuticals to Reverse Consequential Decision on Copay Assistance
News | 3 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe